Annals of Clinical Neurophysiology

"Chronic inflammatory demyelinating polyneuropathy"

Review Article

Insight into the prognostic factors of chronic inflammatory demyelinating polyneuropathy: Seol-Hee Baek; Ann Clin Neurophysiol 2020;22(1):8-12. Published online April 30, 2020; DOI: https://doi.org/10.14253/acn.2020.22.1.8

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated neuropathy with heterogeneous features. Appropriate treatment will produce a favorable outcome, but a poor treatment response and severe disability have also been reported. The roles of the clinical phenotypes and electrophysiological features of CIDP as well as of autoantibodies against nodal and paranodal proteins have been highlighted previously due to their association with the treatment response and long-term prognosis. This review addresses the diverse factors associated with the prognosis of CIDP.

Citations

Citations to this article as recorded by

Tendon-Sparing Extraocular Muscle Enlargement Associated With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Antonios D. Dimopoulos, Anne Barmettler
Ophthalmic Plastic & Reconstructive Surgery.2024; 40(2): e38. CrossRef

7,315 View
201 Download
1 Crossref

Chronic Inflammatory Demyelinating PolyneuropathyAssociated with HIV-Infection: So-Young Huh, Bo-Young Ahn, Se-Jin Oh, Yeong-Eun Park, Dae-Seong Kim; J Korean Soc Clin Neurophysiol 2011;13(2):97-100.

Abstract
PDF

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired immune-mediated polyneuropathy. Corticosteroids,intravenous immunoglobulin (IVIG) and plasmapheresis have been reported to be effective treatment. Rarely, CIDP can occurin the patients with HIV infection. The clinical features and electrophysiological findings of CIDP are known to be similarin patients with and without HIV infection. We report a 30-year-old male with HIV infection associated CIDP who improvedafter the administration of intravenous immunoglobulin and long term oral prednisone.